NASDAQ: PIIIP3 Health Partners Inc Stock
$4.95-0.24 (-4.62%)
Updated Dec 15, 2025
PIII Price
$4.95
Fair Value Price
N/A
Market Cap
$35.67M
52 Week Low
$4.95
52 Week High
$14.50
P/E
-0.12x
P/B
-1.91x
P/S
0.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.44B
Earnings
-$131.05M
Gross Margin
-4.1%
Operating Margin
-5.31%
Profit Margin
-9.1%
Debt to Equity
-35.57
Operating Cash Flow
-$123M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PIII Overview
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PIII's potential to beat the market
- PIII doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
PIII
RankedUnranked of 42
RankedUnranked of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.69 | A | |
| $9.69 | A | |
| $8.89 | A |
Be the first to know about important PIII news, forecast changes, insider trades & much more!
PIII News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PIII scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PIII is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PIII is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
PIII's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more PIII due diligence checks available for Premium users.
Valuation
PIII price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
15.23x
Market
45.07x
PIII price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.91x
Industry
5.31x
PIII's financial health
Profit margin
Revenue
$345.3M
Net Income
-$31.6M
Profit Margin
-9.1%
PIII's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PIII's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$683.6M
Liabilities
$664.6M
Debt to equity
-35.57
PIII's short-term liabilities ($423.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PIII's long-term liabilities ($240.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PIII's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PIII's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.4M
Investing
-$119.0k
Financing
$14.7M
PIII's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PIII vs Medical Care Facility Stocks
P3 Health Partners Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.